{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:56:20Z","timestamp":1783612580057,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["12,13"],"award-info":[{"award-number":["12,13"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["14\u201317"],"award-info":[{"award-number":["14\u201317"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.autrev.2022.103157","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T12:45:28Z","timestamp":1658753128000},"page":"103157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Drugs associated with systemic sclerosis: An updated list of suspected drugs using the WHO pharmacovigilance database"],"prefix":"10.1016","volume":"21","author":[{"given":"Ana\u00ebl","family":"Dumont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dolladille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"de Boysson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Aouba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10103","key":"10.1016\/j.autrev.2022.103157_bb0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet."},{"issue":"10","key":"10.1016\/j.autrev.2022.103157_bb0010","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2022.103157_bb0015","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8314\u20135","key":"10.1016\/j.autrev.2022.103157_bb0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(83)91578-7","article-title":"Genetic susceptibility to scleroderma-like syndrome induced by vinyl chloride","volume":"1","author":"Black","year":"1983","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.autrev.2022.103157_bb0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/1744666X.2016.1125782","article-title":"An overview of environmental risk factors in systemic sclerosis","volume":"12","author":"De Martinis","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103157_bb0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00281-015-0507-3","article-title":"Environmental risk factors of systemic sclerosis","volume":"37","author":"Marie","year":"2015","journal-title":"Semin Immunopathol"},{"issue":"13","key":"10.1016\/j.autrev.2022.103157_bb0035","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJM199003293221302","article-title":"Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan","volume":"322","author":"Silver","year":"1990","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.autrev.2022.103157_bb0040","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/art.22925","article-title":"Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure","volume":"56","author":"Todd","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9234","key":"10.1016\/j.autrev.2022.103157_bb0045","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","article-title":"Scleromyxoedema-like cutaneous diseases in renal-dialysis patients","volume":"356","author":"Cowper","year":"2000","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.autrev.2022.103157_bb0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11926-008-0030-9","article-title":"In perspective: murine models of scleroderma","volume":"10","author":"Wu","year":"2008","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"10.1016\/j.autrev.2022.103157_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2022.103157_bb0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0738-081X(98)00006-6","article-title":"Drug-induced scleroderma and sclerodermiform conditions","volume":"16","author":"Haustein","year":"1998","journal-title":"Clin Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103157_bb0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.alit.2021.08.005","article-title":"Drug-induced scleroderma-like lesion","volume":"71","author":"Hamaguchi","year":"2022","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.autrev.2022.103157_bb0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2230.2004.01668.x","article-title":"Chemotherapy-induced scleroderma: a pleiomorphic syndrome","volume":"30","author":"Alexandrescu","year":"2005","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103157_bb0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2133.2006.07597.x","article-title":"Taxane-induced scleroderma","volume":"156","author":"Itoh","year":"2007","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103157_bb0080","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1111\/1346-8138.13569","article-title":"Taxane-induced scleroderma-like skin changes resulting in gangrene: a case report","volume":"44","author":"Ogawa","year":"2017","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103157_bb0085","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4067\/s0034-98872021000500807","article-title":"Taxane-induced scleroderma. Report of two cases","volume":"149","author":"Cury-Martins","year":"2021","journal-title":"Rev Med Chil"},{"issue":"6","key":"10.1016\/j.autrev.2022.103157_bb0090","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie."},{"issue":"6","key":"10.1016\/j.autrev.2022.103157_bb0095","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.autrev.2022.103157_bb0100","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2022.103157_bb0105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jdermsci.2020.12.007","article-title":"Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma","volume":"101","author":"Aung","year":"2021","journal-title":"J Dermatol Sci"},{"issue":"8","key":"10.1016\/j.autrev.2022.103157_bb0110","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/rheumatology\/kez526","article-title":"In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors","volume":"59","author":"Kitanaga","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2022.103157_bb0115","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00296-021-04956-7","article-title":"Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound","volume":"41","author":"Karalilova","year":"2021","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2022.103157_bb0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/kes303","article-title":"Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies","volume":"52","author":"Bonifazi","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2022.103157_bb0125","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/art.37969","article-title":"Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies","volume":"65","author":"Onishi","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2022.103157_bb0130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.canep.2013.04.014","article-title":"The risk of cancer development in systemic sclerosis: a meta-analysis","volume":"37","author":"Zhang","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103157_bb0135","first-page":"73","article-title":"Cutaneous manifestations of internal malignancy","volume":"59","author":"Thiers","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.autrev.2022.103157_bb0140","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1067\/j.cpsurg.2010.01.003","article-title":"Cutaneous manifestations of internal malignancy","volume":"47","author":"Ehst","year":"2010","journal-title":"Curr Probl Surg"},{"issue":"3","key":"10.1016\/j.autrev.2022.103157_bb0145","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s10067-004-0963-y","article-title":"Systemic sclerosis following oral contraception","volume":"24","author":"Beretta","year":"2005","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103157_bb0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/ard.2008.097378","article-title":"Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts","volume":"68","author":"Soldano","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103157_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.742227","article-title":"Progesterone aggravates lung fibrosis in a mouse model of systemic sclerosis","volume":"12","author":"Vafashoar","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103157_bb0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13075-021-02441-x","article-title":"Elucidating the cellular mechanism for E2-induced dermal fibrosis","volume":"23","author":"Baker Frost","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"30","key":"10.1016\/j.autrev.2022.103157_bb0165","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2022.103157_bb0170","first-page":"6051083","article-title":"Scleroderma renal crisis debute with thrombotic microangiopathy: a successful case treated with eculizumab","volume":"2018","author":"Uriarte","year":"2018","journal-title":"Case Rep Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103157_bb0175","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ekir.2021.01.021","article-title":"Role of C5 inhibition in idiopathic inflammatory myopathies and scleroderma renal crisis-induced thrombotic microangiopathies","volume":"6","author":"Gouin","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1016\/j.autrev.2022.103157_bb0180","first-page":"1939","article-title":"Circulating thrombopoietin in systemic sclerosis","volume":"26","author":"Ertenli","year":"1999","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103157_bb0190","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2022.103157_bb0195","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13023-021-01844-y","article-title":"French recommendations for the management of systemic sclerosis","volume":"16","author":"Hachulla","year":"2021","journal-title":"Orphanet J Rare Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:26:32Z","timestamp":1761600392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222001276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1568997222001276"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103157","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs associated with systemic sclerosis: An updated list of suspected drugs using the WHO pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103157"}}